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Abstract
Background: Basal cell adenocarcinoma accounts for approximately 1.6% of all salivary gland neoplasms. In this
report, we describe our experiences of treatment for BCAC with carbon ion radiotherapy in our institution.
Methods: Case records of 6 patients with diagnosis of basal cell adenocarcinoma of the head and neck, who were
treated by carbon ion radiotherapy with 64.0 GyE/16 fractions in our institution, were retrospectively reviewed.
Results: In a mean follow-up period of 32.1 months (14.0-51.3 months), overall survival and local control rates of
100% were achieved. Only one grade 4 (CTCAE v3.0) late complication occurred. There was no other grade 3 or
higher toxicity.
Conclusions: Carbon ion radiotherapy should be considered as an appropriate curative approach for treatment of
basal cell adenocarcinoma in certain cases, particularly in cases of unresectable disease and postoperative gross
residual or recurrent disease.
Background
Basal cell adenocarcinoma (BCAC) was first recognized
in 1978 and accounts for approximately 1.6% of all sali-
vary gland neoplasms [1]. BCAC typically arises in
adults older than 60 years of age and has no gender pre-
dominance [2]. The vast majority of BCACs occur in the
parotid gland (about 90%) [3-5], followed by the sub-
mandibular gland and minor salivary glands [6]. The
2005 WHO classification categorizes BCAC as a low-
grade tumor with a favorable prognosis [7]. The stan-
dard treatment has been wide local excision with or
without postoperative radiotherapy. However, local
recurrence has frequently been reported.
Carbon ion radiation therapy (C-ion RT) was initiated
at the National Institute of Radiological Sciences (NIRS)
in 1994 [8]. For malignant tumors of the head and neck,
a phase II clinical trial with C-ion RT was started in
April 1997. So far, we have treated more than 350
patients with a large histological variety of malignant
tumors of the head and neck including mainly mucosal
malignant melanoma and adenoid cystic carcinoma. Of
those patients, 6 patients with BCAC of the head and
neck were enrolled. In this report, we describe the 6
patients with BCAC and the efficacy and complications
of C-ion RT.
Methods
Case Presentation
The 6 patients’ characteristics are shown in Table 1.
Mean age was 58 years (range: 37-81 years). None of
the patients had metastasis in distant organs. The pri-
mary sites were parotid gland in 4 patients, base of the
tongue in 1 patient and ethmoid sinus in 1 patient. The
stages for all patients were defined according to Unio
Internationalis Contra Cancrum (UICC) 2002. Histology
of all patients was reconfirmed by a pathologist in our
institution before C-ion RT.
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Patient 1
A 43-year-old Japanese male developed a sore throat
over a period of 3 months. A tumor at the base of the
tongue was detected by endoscopy. The pathological
diagnosis was BCAC by biopsy. CT revealed that the
clinical stage was T4aN0M0 (stage IVA). The diameter
of the primary tumor was 29 mm. At first, one cycle of
chemotherapy, including cisplatin, 5-FU and docetaxel,
was performed in the previous hospital; however, the
tumor did not show shrinkage. He therefore came to
our institution for C-ion RT.
Patient 2
A 70-year-old Japanese male had nasal bleeding for one
week. A tumor in the right ethmoid sinus was detected
by endoscopy and CT in the previous hospital. Biopsy
was performed in the previous hospital, and the diagno-
sis was BCAC (MIB-1 index, 50-80%) in the right eth-
moid sinus with intracranial invasion. The diameter of
the primary tumor was 50 mm and there was no lym-
phadenopathy (cT4aN0M0, s t a g eI V A ) .T h e r ew a sn o
indication for surgery. He came to our institution for
C-ion RT. The patient had bilateral retinal detachments
as a past history.
Patient 3
A 62-year-old Japanese female had undergone right total
parotidectomy in the previous hospital (pT3N0M0, stage
III, R0). The pathological diagnosis was BCAC. There-
after, follow-up was performed every 3 months. Eight
years after parotidectomy, a tumor of 54 mm in dia-
meter was detected under the right temporal skin by
MRI, and BCAC recurrence was confirmed by biopsy.
No lymphadenopathy was detected. There was no indi-
cation for surgery. She came to our institution for C-ion
RT.
Patient 4
A 37-year-old Japanese female developed fullness in the
right ear and right buccal swelling over a period of 3
months. She underwent fine needle biopsy and was diag-
nosed as cytologic class III in the previous hospital. Total
parotidectomy +/- postoperative radiotherapy was
planned. CT revealed that the clinical stage was T3N1M0
(stage III). The diameter of the primary tumor was 54 mm
and the diameter of the right upper cervical lymph node
was 18 mm. However, she declined surgery and requested
C-ion RT. We required the previous hospital to perform
biopsy for confirming the histology. Thereafter, her tumor
was diagnosed as BCAC (MIB-1 index, 10%).
Patient 5
An 81-year-old Japanese male developed left buccal
swelling over a period of one and half years. A benign
tumor was suspected by CT, but the histological diagno-
sis was BCAC by biopsy. The clinical stage was
T4aN0M0 (stage IVA). The diameter of the primary
tumor was 52 mm and there was no lymphadenopathy.
If curative surgery was performed, facial nerve palsy
could not be avoided. For this reason, he declined cura-
tive surgery and selected C-ion RT.
Patient 6
A 55-year-old Japanese male had right buccal swelling.
A benign tumor was suspected and observation was per-
formed. Four years later, a gastric malignant tumor was
found by medical examination. Right partial parotidect-
omy was performed simultaneously with total gastric
resection. The histological diagnosis of the parotid
tumor was BCAC with suspected residual macroscopic
tumor (pT4aN0M0, stage IVA, R2). For gastric cancer,
chemotherapy including TS-1 was performed for 6
months after surgery. However, a gross tumor of 19 mm
in diameter in his right parotid gland remained. He
selected C-ion RT.
Treatment
All of the patients were not indicated for curative sur-
gery or declined surgery, and C-ion RT was performed
as follows.
Table 1 Patients’ Characteristics
Patient Age Gender Primary
Site
Stage (UICC§ 2002) Tumor Response
(RECIST*)
Grade 3 or more Toxicities
(CTCAE† v3.0)
Observation Period
(months)
1 43 M base of
tongue
cT4aN0M0 PR none 25.9
2 70 M ethmoid
sinus
cT4aN0M0 PR Grade 4 retinopathy 20.9
3 62 F parotid
grand
postoperative recurrence
(pT3N0M0, R0)
CR none 14.0
4 37 F parotid
grand
cT3N1M0 PR none 49.6
5 81 M parotid
grand
cT4aN0M0 SD none 51.3
6 55 M parotid
grand
postoperative residual
(pT4aN0M0, R2)
CR none 31.3
Abbreviation, §Unio Internationalis Contra Cancrum; *Response Evaluation Criteria in Solid Tumors; †Common Terminology Criteria for Adverse Events.
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Doses of carbon ions were expressed in photon equiva-
lent doses (GyE), which were defined as the physical
doses multiplied by the RBE of the carbon ions. The
biological flatness of the SOBP was normalized by the
survival fraction of human salivary gland tumor cells at
the distal region of the SOBP, where the RBE of carbon
ions was assumed to be 3.0 [9].
The patients were positioned in customized cradles
(Moldcare; Alcare, Tokyo, Japan) and immobilized with a
low-temperature thermoplastic shell (Shellfitter; Kuraray,
Osaka, Japan). A set of 2.5-mm-thick computed tomogra-
phy (CT) images was taken for treatment planning with
the immobilization devices. CT imaging alone is inade-
quate for detection of extension of the tumor. Therefore,
MRI was routinely used for identification of the tumor,
after fusing it with the planning CT. Determination of
gross target volume (GTV) was based on contrast-
enhanced MRI. The clinical target volume (CTV) had
m i n i m u mm a r g i n so f5 . 0m ma d d e da r o u n dt h eG T V .
The planning target volume (PTV) included margins of
3.0-5.0 mm around the CTV, and this could be modified
manually. The PTV and OAR (e.g., eyeball wall, optic
nerve, optic chiasma and brain stem) were outlined on the
planning CT images to permit dose-volume histogram
(DVH) analysis. Three-dimensional treatment planning
was performed using HIPLAN software (National Institute
of Radiological Sciences, Chiba, Japan) [10]. The PTV was
ensured with at least 95% of the prescription dose.
Irradiation was carried out once per day for 4 days per
week (Tuesday-Friday) with carbon ion beams. The pre-
scribed dose to the center of the CTV was 64.0 GyE/16
fractions over 4 weeks at 4.0 GyE/fraction per day in all
of the 6 patients. Thereafter, no other treatments were
performed for any patients.
Follow-up
The patients were followed up by CT or MRI every 1 or 2
months for the first 6 months after C-ion RT and there-
after every 3 to 6 months. The overall survival and local
control rates were calculated from the first day of C-ion
RT. Toxicities were classified according to Common Ter-
minology Criteria for Adverse Events (CTCAE) v3.0.
Results
All of the patients underwent C-ion RT without an
interval, and all of the patients were alive at the last
observation date. No patient was lost to follow-up. The
mean observation period was 32.1 months (range: 14.0-
51.3 months). There were no local or regional recur-
rences or metastasis in distant organs. Tumor response
rate according to Response Evaluation Criteria in Solid
Tumors (RECIST) was 66.7%, including 1 CR, 3 PR and
2S D ,a t6m o n t h sa f t e rc o m p l e t i o no fC - i o nR T .M R
images of 2 representative patients before and after
C-ion RT and dose-distributions of C-ion RT are shown
in Figures 1 and 2, respectively.
O n ep a t i e n tw h oh a dat u m o ri nt h el e f te t h m o i d
sinus had grade 4 left retinopathy (light perception)
about 12 months after completion of C-ion RT. Three
of the 4 patients who had a tumor in the parotid gland
did not show facial nerve palsy; however one patient
showed slight facial nerve palsy 6 months after C-ion
RT. There was no other grade 3 or higher toxicity in
the 6 patients.
Discussion
Since BCAC seldom metastasizes to cervical lymph
nodes, routine neck dissection is not recommended.
T h em o r t a l i t yr a t ef o rt h i st u mor is also low, although
reported local recurrence rates are high. In a review,
local recurrence was observed in 37% (17/46) of patients
with follow-up between 6 months and 2 years [2]. In
another review, local recurrence was observed in 44.4%
(8/18) of patients with follow-up between 2 years and
14.3 years [11]. From the above experiences, it would
appear that the first treatment of choice for BCAC is
wide local excision with frozen-section control of the
resection margins. However, sufficient resection margins
often cannot to be obtained due to the need for preser-
vation of critical organs (e.g., the facial nerve in parotid
tumors). Therefore, postoperative radiotherapy has been
proposed for lesions with a high risk of vascular and
neural invasion and for lesions that are diffusely infiltra-
tive, especially in patients with close resection margins
[12]. Even with wide local excision and postoperative
radiotherapy, local recurrence has been reported in
about 30-50% of patients (Table 2) [2,11,13]. To our
knowledge, this is the first report of BCAC treated with
radiation alone. Although observation period of the pre-
sent cases was not enough, C-ion RT achieved good
local control among past reports. A possible explanation
for the success we have seen with C-ion RT of BCAC
concerns the differences in biological interactions of car-
bon ion radiation and photon radiation in tissue. Com-
pared to photon radiation, high linear energy transfer
(LET) radiation is characterized by less variation of sen-
sitivity through the cell cycle [14], by less or no repair
of sublethal or potentially lethal cell damage, which is a
problem in controlling repair-proficient photon-resistant
tumors, and by a reduced oxygen enhancement factor
(OER) in the case of hypoxic and poorly-reoxygenating
tumors. An indolent tumor such as BCAC with conse-
quent ability to repair potentially lethal damage from
low LET radiation might have an increased responsive-
ness to C-ion RT. High LET radiation, including C-ion
RT, could be a favorable curative treatment for BCAC.
More long-term observation is required.
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occurred in one patient (patient 2) even with excellent
dose-distribution of C-ion RT since the critical organ
was next to the tumor. We have already revealed the
dose constraints of optic nerves for C-ion RT [15].
Severe retinopathy was considered to be unavoidable in
that patient. Grade 3 or more toxicity was observed in
only that patient. Brown et al. reported that severe facial
nerve palsy occurred in 26% of 66 patients who under-
went surgery even with facial nerve graft for a parotid
neoplasm and postoperative radiotherapy, [16]. On the
other hand, Buchholz et al. reported that facial nerve
palsy occurred in one of 6 patients with recurrent pleo-
morphic adenoma treated by fast neutron radiotherapy,
which is also high LET radiation [17]. Duthoy et al.
reported that decrease of vision occurred in 5 of
39 patients with sinonasal carcinoma treated with
postoperative intensity-modulated radiation therapy
[18]. Compared with those treatment methods, C-ion
RT is considered to be acceptable. However, the average
time of progression to eventual radiation-induced visual
loss was 25.6 months (range, 10-41 months) after C-ion
RT in our previous investigation [15]. Although facial
nerves are considered to be stronger than optic nerves
for C-ion RT since peripheral nerves are known to have
more radio-resistance than central nerves [19], more
facial nerve palsy in patients with a tumor in the parotid
gland may occur in the long term. The acceptable dose
of C-ion RT for facial nerves is currently under
investigation.
Conclusions
We reported preliminary but excellent efficacy of C-ion
RT for BCAC, which is very rare head and neck
Figure 1 Patient 2, a 70-year-old Japanese male with BCAC in the ethmoid sinus. (a) Axial contrast-enhanced T1-weighted MR image
before C-ion RT, (b) Coronal contrast-enhanced T1-weighted MR image before C-ion RT, (c) Histological findings of HE staining at low-
magnification, (d) Histological findings of HE staining at high-magnification, (e) Dose-distribution of C-ion RT in axial and coronal CT images,
(f) Axial contrast-enhanced T1-weighted MR image 1 year after C-ion RT, (g) Coronal contrast-enhanced T1-weighted MR image 1 year after
C-ion RT.
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acceptable toxicities and appreciable efficacy suggest
that C-ion RT could be one of the curative primary
treatments of BCAC.
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Written consent for publication was obtained from all of
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